MERCK & CO., INC. (MRK)
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens
📈 **POSITIVE** • Medium confidence analysis (69%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business